• Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as to determine the efficacy of the regimen in patients with high-risk leukemia and myelodysplasia. (sparkcures.com)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Myeloablative allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure usually accompanied by multifactorial malnutrition, prompting the recommendation of systematic artificial nutritional support. (biomedcentral.com)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure, and is usually conducted to consolidate remission of haematological malignancies. (biomedcentral.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • An essential component of allogeneic and autologous hematopoietic stem cell transplantation (HSCT) is the conditioning regimen administered before the hematopoietic cell infusion. (org.in)
  • This post is about basic concepts of conditioning regimens in allogeneic HSCT. (org.in)
  • Hematopoietic stem cell transplantation (HSCT) has been shown to be effective. (medscape.com)
  • In the prospective Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3 comparison of autologous HSCT with 12 successive monthly intravenous pulses of cyclophosphamide in 156 patients with early diffuse cutaneous systemic sclerosis, HCST was associated with higher treatment-related mortality than in the first year after treatment. (medscape.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment for acute myeloid leukemia patients. (oncotarget.com)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Hepatitis B virus (HBV) flare is a serious problem following hematopoietic stem cell transplantation (HSCT), and the mortality rate is high if severe hepatitis occurs. (springeropen.com)
  • Hepatitis B virus (HBV) flare and reactivation after hematopoietic stem cell transplantation (HSCT) is a life-threatening complication in patients with HBV infection (Liang et al. (springeropen.com)
  • Currently, the only effective treatment option for patients with CALD is allogeneic hematopoietic stem cell transplant. (globalgenes.org)
  • Currently, allogeneic hematopoietic stem cell transplant is the only available therapy-but one that presents challenges for patients without a matched sibling donor," said David Williams, principal investigator of the study. (globalgenes.org)
  • Most adverse events occurred during the two weeks post-transplant and most were associated with myeloablative chemotherapy. (globalgenes.org)
  • Successful outcomes following allogeneic hematopoietic cell transplant (HCT) may be offset by risks of transplant-related morbidity and mortality. (haematologica.org)
  • 1 Traditional factors used to gauge transplant risks include conditioning regimen intensity, 2 immunosuppression and HLA matching, 3 along with hematopoietic cell source, and graft cell yield. (haematologica.org)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • At 4 years of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte and natural killer cell numbers. (frontiersin.org)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Growing evidence demonstrates that various cancer treatment modalities, including chemotherapy, radiation therapy, targeted therapy, immunotherapy, hormone therapy, stem cell or bone marrow transplant, and surgery [ 3 - 5 ] , cause premature senescence, as reviewed elsewhere [ 6 - 8 ] . (oaepublish.com)
  • Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. (scielo.org)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • In view of the disseminated CMV infection, the decision was made to infuse stem cells without any pre-conditioning chemotherapy. (frontiersin.org)
  • Neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. (medicines.org.uk)
  • Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. (ucsf.edu)
  • Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. (ucsf.edu)
  • The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month. (ucsf.edu)
  • The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. (biomedcentral.com)
  • Because there is no effective chemotherapeutic regimen for intrathoracic malignant neurogenic tumor, all three patients received high-dose chemotherapy followed by hematopoietic stem cell transplantation. (springeropen.com)
  • PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. (bms.com)
  • CheckMate -331 is an open-label, randomized Phase 3 study evaluating Opdivo monotherapy versus chemotherapy in patients with relapsed small cell lung cancer (SCLC) following platinum-based chemotherapy. (bms.com)
  • The overall response rate to first-line therapies with anthracycline-based regimens was poor (32%), with a median survival of only 6.9 months. (oncotarget.com)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • Neupogen is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). (medicines.org.uk)
  • The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed. (medicines.org.uk)
  • Abstract Introduction: Graft-versus-host disease (GVHD) is a serious complication in allogeneic transplantation. (scielo.org)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • At the time they performed the first transplants surprisingly little was known about hematopoietic stem cells, immune responses to transplants or the complex human leucocyte antigen system. (revistadehematologia.org.mx)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). (wikipedia.org)
  • CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. (wikipedia.org)
  • Less commonly, the disease comes to light only after the cancerous cells overwhelm the bone marrow, resulting in low red blood cells, neutrophils, or platelets. (wikipedia.org)
  • Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • [18] Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
  • 1 , 2 , 4 - 6 Specifically, patients with lactate dehydrogenase ≥2 times the upper limit of normal (ULN) at diagnosis, R/R disease within 6 months of diagnosis, multisite relapse, and/or R/R disease with bone marrow involvement experience a significantly decreased OS ( Table 1 ). (jnccn.org)
  • Giant cell tumor is a benign bone tumor, locally aggressive with low malignant potential. (jbstjournal.com)
  • Giant cell tumors (GCT) of the bone are aggressive and are recognised for variable clinical behaviour, which is not always related to radiographic or histological appearance [1]. (jbstjournal.com)
  • Giant cell tumor (GCT) of bone is a benign but locally aggressive tumor with tendency for local recurrence [2]. (jbstjournal.com)
  • Campanacci's staging system for giant cell tumour of the bone [5] was used for cortical breach. (jbstjournal.com)
  • Bone Marrow Transplantation. (bvsalud.org)
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. (scielo.org)
  • Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. (medscape.com)
  • The underlying pathophysiology in AML consists of a maturational arrest of bone marrow cells in the earliest stages of development. (medscape.com)
  • Patients with AML present with symptoms resulting from bone marrow failure, symptoms resulting from organ infiltration with leukemic cells, or both. (medscape.com)
  • Second, the rapid proliferation of these cells, along with a reduction in their ability to undergo programmed cell death (apoptosis), results in their accumulation in the bone marrow, the blood, and, frequently, the spleen and liver. (medscape.com)
  • MDS is a bone marrow disease of unknown etiology that occurs most often in older patients and manifests as progressive cytopenias that occur over months to years. (medscape.com)
  • FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • Bluebird Bio said interim results from an initial cohort of 17 patients in the ongoing phase 2/3 study Lenti-D, its experimental gene therapy in boys with cerebral adrenoleukodystrophy, or CALD, a potentially fatal disease that causes a breakdown in the protective sheath of nerve cells in the brain responsible for thinking and muscle control. (globalgenes.org)
  • We explored whether stem cell therapy was effective for animal models and patients with Crohn's disease (CD). (biomedcentral.com)
  • Stem cell transplantation is a valuable supplementary therapy for CD. (biomedcentral.com)
  • Several studies have evaluated the safety and effectiveness of CD stem cell therapy, but the results remain controversial. (biomedcentral.com)
  • This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort. (oncotarget.com)
  • 0.5 x 109 cells/kg and being transplanted in CR1 versus CR/PR from second-line therapy were identified as independent predictors for OS and PFS. (astct.org)
  • The only curative therapy is hematopoietic stem cell transplantation. (frontiersin.org)
  • An experienced multidisciplinary team in close consultation with the primary transplantation centre should perform the rehabilitation therapy. (mdpi.com)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Iodine-131-metaiodiobenzylguanidine ( 131 I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. (biomedcentral.com)
  • Based on our findings, we suggest that 131 I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible. (biomedcentral.com)
  • Transplantation and Cellular Therapy. (elsevierpure.com)
  • Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? (biomedcentral.com)
  • Bristol-Myers Squibb has a broad development program in thoracic malignancies, including SCLC, non-small cell lung cancer and malignant pleural mesothelioma. (bms.com)
  • CLL has also been reported to convert into other more aggressive diseases such as lymphoblastic lymphoma, hairy cell leukemia, high grade T cell lymphomas, acute myeloid leukemia, lung cancer, brain cancer, melanoma of the eye or skin, salivary gland tumors, and Kaposi's sarcomas. (wikipedia.org)
  • The primary safety endpoint is the proportion of patients who experience grade 2+ acute graft vs. host disease or chronic graft vs. host disease at 24 months post-treatment. (globalgenes.org)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • High risk of acute pulmonary toxicity with both myeloablative and non-myeloablative total body irradiation-based conditioning for allogeneic stem cell transplantation. (dukecancerinstitute.org)
  • This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). (ucsf.edu)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
  • OBJECTIVES: Haematopoietic cell transplantation (HCT) preceded by a conditioning regimen is an established treatment option for (non)malignant haematologic disorders. (bvsalud.org)
  • In contrast, non-Hodgkin lymphoma is best regarded as a systemic disease, because of the unique anatomy of the lymphoid system and because of the physiology of lymphoid cells, which tend to migrate whether they are normal or malignant. (medscape.com)
  • The primary efficacy endpoint for the study is the proportion of patients who are alive and have no major functional disabilities at 24 months post drug product infusion. (globalgenes.org)
  • Stem cell infusion is a relatively simple process that is performed at the bedside. (medscape.com)
  • An A-ALC cell infusion containing 0.5 x 109 cells/kg was chosen as a cutoff to evaluate for prognosis. (astct.org)
  • She received a matched sibling donor unconditioned stem cell infusion at 16 months of age. (frontiersin.org)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered? (mdpi.com)
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
  • This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL). (ucsf.edu)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
  • In recent years, developments in stem cell (SC) biology and regenerative medicine have revealed that SCs unexpectedly can be used to treat autoimmune diseases. (biomedcentral.com)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • However, HLA-identical sibling stem cell infusions in ADA-SCID result in some donor stem cell engraftment and long-term thymopoiesis. (frontiersin.org)
  • There was 93% donor T-lymphocytes, 20% donor B-lymphocytes, and 5% donor myeloid cells, indicative of some donor stem cell engraftment. (frontiersin.org)
  • The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
  • Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. (ucsf.edu)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • Telomeric DNA damage response induced by some cancer treatments can persist for months, possibly accounting for long-term sequelae of cancer treatments. (oaepublish.com)
  • Sabine Maier, M.D., development lead, thoracic cancers, Bristol-Myers Squibb, commented, "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains. (bms.com)
  • Small cell lung cancer (SCLC) is one of two main types of lung cancer and accounts for about 10% to 15% of all lung cancers. (bms.com)
  • In cultured primary fibroblasts and cancer cells, the chemotherapeutic drug doxorubicin causes mtDNA damage and release, which leads to cGAS STING dependent ISG activation. (regenerativemedicine.net)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • Hallmarks of the postengraftment period, which lasts for months to years, include the gradual development of tolerance, weaning off of immunosuppression, management of chronic GVHD, and documentation of immune reconstitution. (medscape.com)
  • Myeloablative conditioning is recommended to prevent rejection caused by residual immune function. (frontiersin.org)
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • We are leading the integrated scientific understanding of both tumor cell and immune system pathways, through our extensive portfolio of investigational compounds and approved agents. (bms.com)
  • All patients achieved initial mixed hematopoietic chimerism with two patients rejecting their graft and recovering host hematopoiesis. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • We studied 5 consecutive cases of GCT involving the distal radius operated by en-bloc resection of tumor followed by reconstruction with ipsilateral non-vascularized fibular graft with a minimum 1 year follow-up. (jbstjournal.com)
  • Each of those cell sources has specific advantages and disadvantages, and each has found particular clinical applications. (medscape.com)
  • In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • The American Society of Parenteral and Enteral Nutrition (ASPEN) and the French-speaking society of clinical nutrition and metabolism (SFNEP) recommend nutritional support during haematopoietic transplantation for patients who are malnourished or have decreased intake or decreased intestinal absorption over a prolonged period (grade B) [ 11 , 12 ]. (biomedcentral.com)
  • OBJECTIVES: To describe the morphologic characteristics of skin lesions, extent of extracutaneous disease, and outcomes in patients with neonatal presentation of Langerhans cell histiocytosis (LCH), and to examine clinical predictors of disease prognosis. (thedoctorsdoctor.com)
  • This exceeds the pre-defined efficacy success benchmark for the study of 76 percent major functional disability-free survival at 24 months for this initial subset of patients. (globalgenes.org)
  • 6 Comorbidity determined by the hematopoietic cell transplantation-comorbidity index (HCT-CI), 7 predicts for worse survival, generally through higher TRM. (haematologica.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • From the time of diagnosis, the median range of survival for extensive-stage SCLC (ES-SCLC) patients is between eight and 13 months. (bms.com)
  • The rehabilitation centres should be qualified and experienced because this patient group exhibits problems that differ from those of patients who have undergone oncological therapies or autologous HCT. (mdpi.com)
  • Such viruses promote anti-tumor responses through a dual mechanism of action that is dependent on selective tumor cell killing and the induction of systemic anti-tumor immunity. (bms.com)
  • The primary endpoint will assess the effect of EN on D100 mortality. (biomedcentral.com)
  • The rapidity of his disease progression suggests it would have been difficult to alter his early neurological decline given that Lenti-D treatment takes months to exert a therapeutic effect in CALD. (globalgenes.org)
  • In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. (biomedcentral.com)
  • 1992). Since then, hematopoietic stem cells, with their unique ability to differentiate into various blood cell types, have proven to be a revolutionary tool in the treatment of numerous hematological disorders. (revistadehematologia.org.mx)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • EN and PN need to be prospectively compared in order to assess their impacts and to provide treatment guidelines. (biomedcentral.com)
  • We will validate this predictive panel on 300 matched cGvHD patients samples pre-treatment and 3 months post-treatment. (cryostem.org)
  • Secondary endpoints will compare EN and PN with regards to the main haematological, infectious and nutritional outcomes. (biomedcentral.com)
  • This subtype, termed chronic lymphocytic leukemia-type MBL (CLL-type MBL) is an asymptomatic, indolent, and chronic disorder in which people exhibit a mild increase in the number of circulating B-cell lymphocytes. (wikipedia.org)
  • Chronic lymphocytic leukemia may also develop a Richter's transformation i.e. conversion to a far more aggressive form that has the histopathology of diffuse large B cell lymphoma or Hodgkin's lymphoma. (wikipedia.org)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • 6 Center for Stem Cell & Regenerative Medicine, The University of Texas Health Science Center of Houston, TX 77030, USA. (oaepublish.com)
  • Enadenotucirev is a virus that selectively replicates in tumor cells but not in normal cells. (bms.com)